

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	10/591,486
Filing Date	June 18, 2007
First Named Inventor	Michael Dake
Art Unit	1656
Examiner Name	Marsha Tsay
Attorney Docket Number	13720-105068US2

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		6,447,787	09-10-2002	Gassner et al.	
		6,458,763	10-01-2002	Peterson et al.	
		6,627,632	09-30-2003	Parks et al.	
		6,688,311	02-10-2004	Hanin	
		6,855,688	02-15-2005	McKerracher	
		6,958,147	10-25-2005	Alitalo et al.	
		7,138,105	11-21-2006	Bolotin	
		2003/0109448	06-12-2003	Crowley et al.	
		2004/0109871	06-10-2004	Pascual	

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	† <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		JP 63-287730 (Abstract Only)	11-24-1988	Nippon Shokubai Kagaku Kogyo Co. Ltd.		x
		JP 2002-524527 (English translation in counterpart WO 00/15245)	08-06-2002	Elian Pharmaceuticals, Inc.		x
		JP 11-60475 (English translation in counterpart US 2002/0150613)	03-02-1999	Verteq Inc.		x
		WO 2004/006954	01-22-2004	Allergan		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered; otherwise not citation is in conformance with MPEP 806. Drawings through citation if not in conformance and not considered. Include copy of this form with most recent communication to applicant. Applicant's unique citation designation number (optional). <sup>1</sup>See Kinds Codes in USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>2</sup>Enter Office first received the document by the two letter code (WIPO Standard ST 3). <sup>3</sup>For Japanese cited documents, the indication of the year of the receipt of the European patent precedes the serial number of the patent document. <sup>4</sup>Serial of document by the appropriate symbol as indicated on the document under WIPO Standard ST 16 if possible. <sup>5</sup>Applicant is to place a check mark (x) in English language translation is affixed. <sup>6</sup>This selection of references is required by 37 CFR 1.57 and 1.58. This information is required to make or issue a benefit by the patent which is to be used by the USPTO to prepare an application. Confidentiality is provided by 35 U.S.C. 127 and 17 CFR 1.14. This information is intended to be used to complete, including preparing, preparing, and submitting the completed application form to the USPTO. Your job is to determine if the information is relevant. Your statement on the amount of time was required to complete this form under suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1400, Alexandria, VA 22315-1400; OR NOT SEND PRESS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissioner for Patents, P.O. Box 1400, Alexandria, VA 22315-1400.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

### Complete If Known

Application Number	10/591,486
Filing Date	June 18, 2007
First Named Inventor	Michael Dake
Art Unit	1656
Examiner Name	Marsha Tsay
Attorney Docket Number	13720-105068US2

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Futaki et al., "Internalization of Branched Arginine Peptides into Cells," 27[P1]-120, The Pharmaceutical Society of Japan, Abstract, 123(2), March 2003	x
		Futaki, "Intracellular Delivery of Biopolymers Using Membrane-Permeable Peptides," Membrane, 28(2), pp. 55-60, 2003	x
		Futaki et al., "Novel Method for Introducing Protein into Cells Using Arginine Peptides," 27[P1]-118, Institute for Chemical Research, 123(2), p. 26, March 2003	x
		Park et al., "Mutational Analysis of a Human Immunodeficiency Virus Type 1 TAT Protein Transduction Domain Which is Required for Delivery of a Exogenous Protein into Mammalian Cells," Journal of General Virology, 83, pp. 1173-1181, 2002	
		Somerman et al., Human Bone Sialoprotein I and II Enhance Fibroblast Attachment in Vitro," Calcif. Tissue Intl., 43, pp. 50-53, 1988	
		Umezawa et al., "Development of $\beta$ -peptides Having Ability to Penetrate Cell Membrane," 27[P1]-133, Faculty of Pharmaceutical Sciences, Nagoya City University, 123(2), p. 29, March 2003	
		Communication Pursuant to Article 94(3) EPC issued for European Patent Appln. No. 05759520.9 dated October 1, 2010	
		Communication Pursuant to Article 94(3) EPC issued for European Patent Appln. No. 05724470.9 dated October 19, 2010	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Omit the slash through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbol as indicated on the document under WPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached. This reference of information is required by 37 CFR 1.91 and 1.96. The information is required to issue a benefit by the public which is in the hand by the USPTO to process an application. Confidentiality is provided by 35 USC 122 and 37 CFR 1.14. This reference is intended to take action to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any responses or the status of these are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22311-1450. DO NOT SEND FILES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: [Commaohow for Patents, P.O. Box 1450, Alexandria, VA 22311-1450](mailto:Commaohow for Patents, P.O. Box 1450, Alexandria, VA 22311-1450).